Helixon (Earendil Labs)

People

Only people the AI4S.fyi record has named: in a round, a timeline entry, commentary, an interview or a sourced role. Not the full team.

Funding rounds tracked

• 2026-03-20Round (unnamed) · $787MconfirmedWith Dimension Capital, DST Global, INCE Capital, Luminous Ventures, Sanofi, Biotech Development Fund (Hillhouse and Pfizer), Miracle Capital, Gaorong Capital, Xianghe CapitalStated use: scale AI biologics R&D; move multiple programs toward the clinic
• 2022-06-22Series A · nearly 500 million yuanconfirmedLed by 5Y Capital · With Gaorong Capital, Neumann Capital, Xianghe Capital, GL Ventures, Qingzhi CapitalStated use: team, business development, AI compute, high-throughput lab, pipeline
• 2021-10-20Angel · tens of millions of US dollarsconfirmedLed by Xianghe Capital · With GL Ventures, Qingzhi Capital

Each round links to its line on the funding record, with its source.

Also in Protein design on the funding board

The other companies the funding board files under the same field, latest round first. A list of what the record tracks, not a ranking or a market map.

• 2026-10-28BioGeometrySeries A+ · not disclosed; the A series to date tops $100MBuilds generative models for biology: GeoFlow, an all-atom model that predicts the structures of proteins and their complexes and designs binders, and GeoCell, a virtual-cell model of how cells' gene expression responds to genetic and drug perturbations. An automated lab expresses and tests the designs and feeds the data back. It designs antibodies, vaccines, peptides and enzymes for partners and its own pipeline, including synthetic-biology products.
• 2026-09-24BigHat BiosciencesSeries C · $75MDesigns antibodies with machine learning tied to a fast automated wet lab (Milliner) that makes and tests designs; its lead drug BHB810 is in the clinic.
• 2026-08-11Aureka BiotechnologiesSeries B · $100MDesigns antibodies with its own biological foundation model, AuraIDE (released in open form as OpenDDE), trained and retrained on data from its own single-cell functional screens.
• 2026-07-14Chai DiscoverySeries C · $400MBuilds AI models that predict how molecules bind and design antibodies from scratch, and licenses them to drugmakers as software.
• 2026-06-17MoleculeMindSeries A (extension) · A-series cumulative total over US$100 millionAI protein structure prediction and design (MoleculeOS, MMFold, MMDesign) sold to drugmakers and industrial-enzyme users, with a few in-house early programs.
• 2026-02-26Generate:BiomedicinesIPO · $400MA Flagship company using generative AI to design protein drugs such as antibodies, peptides and enzymes, and developing them itself.

All 15 in this field →